Stockreport

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March [Read more]